For the past week, we have fielded several phone calls and emails asking us about the status of our clinical data for our Phase IIb study in treating Adrenomyeloneuropathy (AMN). While we are working diligently to get this information compiled, analyzed, and published as quickly as possible, it has taken a little longer than expected due to a lag in data collection from the last several patients in the Trial.

We understand how anxious and excited you are to learn more about the results of this trial. We are too! Please bear with us as we continue to process the data. We expect to have it available towards the end of October.

Update: November 17, 2008

The last patient’s visit occurred in August 2008 and currently, the data from the trial are being prepared for analysis, with results expected during early 2009.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Update on the Phase IIb Clinical Trial Data", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

1 Comment

Dear Madame,
Dear Sir,

One of my patients has the disease
adrenomyeloneuropathy
I am looking forward to hear from you, your clinical results
Yours faithfully,
dr. E. de Winter
neurosurgeon

Comment by dr. E. De Winter — October 29, 2008 @ 9:38 am

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website